NCT00119600
Terminated
Phase 1
A Randomised, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Finding Study of AMG 114 Administered by Subcutaneous Injection for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle Chemotherapy
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Anemia
- Sponsor
- Amgen
- Primary Endpoint
- Incidence and severity of adverse events
- Status
- Terminated
- Last Updated
- 16 years ago
Overview
Brief Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of AMG 114 administered subcutaneously for the treatment of chemotherapy induced anemia in subjects receiving multicycle chemotherapy.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Part A: - Non-myeloid malignancy receiving multicycle chemotherapy - Receiving non-platinum containing chemotherapy - At least 6 additional weeks of cyclic cytotoxic chemotherapy planned Part B and Part C: - Non-myeloid malignancy receiving multicycle chemotherapy - At least 12 additional weeks of cyclic cytotoxic chemotherapy planned All Parts: - Chemotherapy induced anemia - Greater than 6 month life expectancy - ECOG 0-2 - Adequate renal and liver function
Exclusion Criteria
- •Chronic myeloid leukemia, AML, ALL, Burkitt's lymphoma or lymphoblastic lymphoma - History of seizure disorder - Primary hematologic disorder which could cause anemia, other than a non-myeloid malignancy - Unstable angina, congestive heart failure or uncontrolled cardiac arrhythmia - Uncontrolled hypertension - History of pure red cell aplasia - Clinically significant inflammatory disease or active infection - Iron deficiency - ANC less than 0.8 x 10\^9 cells/L
Outcomes
Primary Outcomes
Incidence and severity of adverse events
Change in hemoglobin concentration
Maximum observed concentration (Cmax)
Time Cmax is observed (Tmax)
AUC
Secondary Outcomes
- Change in FACT-fatigue sub-scores
Similar Trials
Completed
Phase 1
Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease SubjectsCrohn's DiseaseNCT01258205AstraZeneca48
Completed
Phase 1
A First-in-human Study Evaluating AMG 167 in Healthy Men and Postmenopausal WomenOsteopeniaNCT00902356Amgen69
Terminated
Phase 1
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Adults With PsoriasisPsoriasisNCT01493518Amgen6
Completed
Phase 2
Safety, Tolerability, and Clinical Activity of ASM-024 Administered to Patients With GOLD 2 or GOLD 3 Chronic Obstructive Pulmonary Disease (COPD)COPDNCT01855230Asmacure Ltée14
Completed
Phase 2
Study of HGF Via Plasmid Vector to Improve Perfusion in Critical Limb IschemiaArterial Occlusive DiseasePeripheral Vascular DiseaseIschemiaNCT00060892AnGes USA, Inc.104